The concordance of drugs receiving a priority
review in Canada with those in the United States was evaluated
using sensitivity (the percentage of drugs with priority review
status in the United States that received the same status in Canada),
specificity (the percentage of standard review drugs in the United
States that received the same type of review in Canada)